MX2023010120A - Formulaciones de polvo seco de dihidroergotamina y metodos de uso. - Google Patents
Formulaciones de polvo seco de dihidroergotamina y metodos de uso.Info
- Publication number
- MX2023010120A MX2023010120A MX2023010120A MX2023010120A MX2023010120A MX 2023010120 A MX2023010120 A MX 2023010120A MX 2023010120 A MX2023010120 A MX 2023010120A MX 2023010120 A MX2023010120 A MX 2023010120A MX 2023010120 A MX2023010120 A MX 2023010120A
- Authority
- MX
- Mexico
- Prior art keywords
- dry powder
- methods
- dihydroergotamine
- powder formulations
- dry
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163156111P | 2021-03-03 | 2021-03-03 | |
| PCT/US2022/018306 WO2022187222A1 (en) | 2021-03-03 | 2022-03-01 | Dihydroergotamine dry power formulations and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023010120A true MX2023010120A (es) | 2023-10-30 |
Family
ID=80781023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023010120A MX2023010120A (es) | 2021-03-03 | 2022-03-01 | Formulaciones de polvo seco de dihidroergotamina y metodos de uso. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240033218A1 (https=) |
| EP (1) | EP4301334A1 (https=) |
| JP (1) | JP2024510564A (https=) |
| KR (1) | KR20230152083A (https=) |
| CN (1) | CN117222401A (https=) |
| AU (2) | AU2022228443B2 (https=) |
| BR (1) | BR112023017538A2 (https=) |
| CA (1) | CA3210442A1 (https=) |
| IL (1) | IL305506A (https=) |
| MX (1) | MX2023010120A (https=) |
| WO (1) | WO2022187222A1 (https=) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4069819A (en) | 1973-04-13 | 1978-01-24 | Societa Farmaceutici S.P.A. | Inhalation device |
| IT1228459B (it) | 1989-02-23 | 1991-06-19 | Phidea S R L | Inalatore con svuotamento regolare e completo della capsula. |
| WO2008097664A1 (en) * | 2007-02-11 | 2008-08-14 | Map Pharmaceuticals, Inc. | Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile |
| AP3138A (en) * | 2009-04-24 | 2015-02-28 | Iceutica Pty Ltd | Production of encapsulated nanoparticles at high volume fractions |
| CN103200938B (zh) * | 2010-08-30 | 2018-07-31 | 普马特里克斯营业公司 | 干燥粉末配方及用于治疗肺部疾病的方法 |
| PT3470057T (pt) * | 2010-09-29 | 2021-12-03 | Pulmatrix Operating Co Inc | Pós secos catiónicos compreendendo sais de magnésio |
| AU2013361337A1 (en) * | 2012-12-21 | 2015-07-09 | Map Pharmaceuticals, Inc. | 8'-Hydroxy-Dihydroergotamine compounds and compositions |
| US20140179705A1 (en) * | 2012-12-21 | 2014-06-26 | Map Pharmaceuticals, Inc. | 8'-hydroxy-dihydroergotamine compounds and compositions |
| AU2014248455B2 (en) * | 2013-04-01 | 2018-12-06 | Pulmatrix Operating Company, Inc. | Tiotropium dry powders |
| IL265913B2 (en) * | 2016-10-14 | 2024-07-01 | Pulmatrix Operating Co Inc | Respirable Dry Powder Comprising Itraconazole In Crystalline Form And Its Use For Manufacturing A Medicament For Treating Fungal Infection |
-
2022
- 2022-03-01 BR BR112023017538A patent/BR112023017538A2/pt unknown
- 2022-03-01 CN CN202280031563.XA patent/CN117222401A/zh active Pending
- 2022-03-01 IL IL305506A patent/IL305506A/en unknown
- 2022-03-01 MX MX2023010120A patent/MX2023010120A/es unknown
- 2022-03-01 JP JP2023553124A patent/JP2024510564A/ja active Pending
- 2022-03-01 AU AU2022228443A patent/AU2022228443B2/en active Active
- 2022-03-01 KR KR1020237032645A patent/KR20230152083A/ko active Pending
- 2022-03-01 EP EP22710901.4A patent/EP4301334A1/en active Pending
- 2022-03-01 US US18/548,896 patent/US20240033218A1/en active Pending
- 2022-03-01 WO PCT/US2022/018306 patent/WO2022187222A1/en not_active Ceased
- 2022-03-01 CA CA3210442A patent/CA3210442A1/en active Pending
-
2025
- 2025-10-21 AU AU2025256073A patent/AU2025256073A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL305506A (en) | 2023-10-01 |
| EP4301334A1 (en) | 2024-01-10 |
| WO2022187222A1 (en) | 2022-09-09 |
| AU2025256073A1 (en) | 2025-11-13 |
| JP2024510564A (ja) | 2024-03-08 |
| CA3210442A1 (en) | 2022-09-09 |
| US20240033218A1 (en) | 2024-02-01 |
| AU2022228443A1 (en) | 2023-09-21 |
| KR20230152083A (ko) | 2023-11-02 |
| AU2022228443B2 (en) | 2025-07-24 |
| WO2022187222A8 (en) | 2023-11-02 |
| CN117222401A (zh) | 2023-12-12 |
| BR112023017538A2 (pt) | 2023-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020014315A (es) | Compuestos de heteroarilo para tratar la enfermedad de huntington. | |
| CL2019000815A1 (es) | Compuestos arilo o heteroarilo sustituidos con amino como inhibidores de ehmt1 y ehmt2. (divisional solicitud 201802928). | |
| CL2015002787A1 (es) | Formulación de acetato de abiraterona. | |
| MY202008A (en) | Crystalline and salt forms of ppar agonist compounds | |
| MX2021001091A (es) | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington. | |
| PE20190377A1 (es) | Formulaciones de un inhibidor de lsd 1 | |
| WO2018226622A8 (en) | Compounds for treating huntington's disease | |
| MX2018011371A (es) | Dispositivo de plasma frio para tratar la piel. | |
| MX2017001646A (es) | Metodo y sistema para reconstruir porciones del rostro obstruidas para entorno de realidad virtual. | |
| NZ762628A (en) | Dioxolane analogues of uridine for the treatment of cancer | |
| BR112017006653A2 (pt) | método para tratamento de um substrato animal | |
| MY192703A (en) | Compositions containing tucaresol or its analogs | |
| MX2017010544A (es) | Metodos y composiciones para tratar la enfermedad del ojo seco y otros trastornos del ojo. | |
| MX2015013845A (es) | Polvos secos de tiotropio. | |
| WO2014152782A3 (en) | Substantially surfactant-free, submicron dispersions of hydrophobic agents containing high levels of water miscible solvent | |
| MX386216B (es) | Uso de estimuladores de guanilato ciclasa soluble (sgc) para el tratamiento de esteatohepatitis no alcohólica (nash). | |
| CL2018002432A1 (es) | Composición de fertilizante recubierto con pulverización | |
| CL2019001426A1 (es) | Composiciones y métodos relacionados con agonistas de piridinoilpiperidina 5-ht1f. | |
| AR110179A1 (es) | Métodos para un aislamiento zonal y divergencia del tratamiento | |
| CL2016000180A1 (es) | Composición antituberculosa que comprende rifampicina, isoniazid, etambutol y pirazinamida y su proceso de preparación | |
| SV2018005702A (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer | |
| GB2562984A (en) | Hydrate inhibitors and methods of use | |
| GB2562679A (en) | Double-headed hydrate inhibitors and methods of use | |
| BR112018069504A2 (pt) | composto de sultam e método de aplicação do mesmo | |
| MX2023010120A (es) | Formulaciones de polvo seco de dihidroergotamina y metodos de uso. |